Literature DB >> 22491505

Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis.

Sóstenes Mistro1, Isis de M Maciel, Rouseli G de Menezes, Zuinara P Maia, Robert T Schooley, Roberto Badaró.   

Abstract

This meta-analysis of 13 studies revealed that amphotericin B delivered as a locally prepared lipid emulsion or in liposomes reduced nephrotoxicity to a similar degree, by 18.4% (relative risk [RR], 0.40 [99% confidence interval, .25-.64]; n = 459) and 18.1% (RR, 0.48 [99% CI, .36-.64]); n = 1233), respectively.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22491505     DOI： 10.1093/cid/cis290

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  21 in total

Review 1.  Endemic mycoses in patients with STAT3-mutated hyper-IgE (Job) syndrome.

Authors:  Camila D Odio; Ki Lee Milligan; Katherine McGowan; Amanda K Rudman Spergel; Rachel Bishop; Lisa Boris; Amanda Urban; Pamela Welch; Theo Heller; David Kleiner; Mary Anne Jackson; Steven M Holland; Alexandra F Freeman
Journal:  J Allergy Clin Immunol       Date:  2015-08-17       Impact factor: 10.793

2.  A clinical pharmacist survey of prophylactic strategies used to prevent adverse events of lipid-associated formulations of amphotericin B.

Authors:  Daniel B Chastain; Rachele L Giles; Christopher M Bland; Carlos Franco-Paredes; Andrés F Henao-Martínez; Henry N Young
Journal:  Infect Dis (Lond)       Date:  2019-02-18

3.  Incidence, Predictors, and Impact on Hospital Mortality of Amphotericin B Nephrotoxicity Defined Using Newer Acute Kidney Injury Diagnostic Criteria.

Authors:  Paulo Novis Rocha; Carla Dinamérica Kobayashi; Luna de Carvalho Almeida; Camilla de Oliveira Dos Reis; Barbara Mendes Santos; Marshall Jay Glesby
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

Review 4.  Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity.

Authors:  Iman Karimzadeh; Hossein Khalili; Shadi Farsaei; Simin Dashti-Khavidaki; Mohammad Mahdi Sagheb
Journal:  Eur J Clin Pharmacol       Date:  2013-01-30       Impact factor: 2.953

Review 5.  Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.

Authors:  Neil R H Stone; Tihana Bicanic; Rahuman Salim; William Hope
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

6.  Comparison of adverse events and hospital length of stay associated with various amphotericin B formulations: sequential conventional amphotericin b/lipid versus lipid-only therapy for the treatment of invasive fungal infections in hospitalized patients.

Authors:  Rolin L Wade; Paresh Chaudhari; Jaime L Natoli; Robert J Taylor; Brian H Nathanson; David Horn
Journal:  P T       Date:  2013-05

Review 7.  An Italian consensus for invasive candidiasis management (ITALIC).

Authors:  L Scudeller; C Viscoli; F Menichetti; V del Bono; F Cristini; C Tascini; M Bassetti; P Viale
Journal:  Infection       Date:  2013-11-25       Impact factor: 3.553

Review 8.  Design of amphotericin B oral formulation for antifungal therapy.

Authors:  Min Liu; Meiwan Chen; Zhiwen Yang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

9.  Sinonasal mucormycosis and liposomal amphotericin B: A quest for dose optimization.

Authors:  Smile Kajal; Syed Shariq Naeem; Pooja Gupta; Arvind Kumar Kairo; Anam Ahmed; Prankur Verma; Ashish Saini
Journal:  Indian J Pharmacol       Date:  2022 Mar-Apr       Impact factor: 2.833

10.  Outcomes associated with conventional versus lipid-based formulations of amphotericin B in propensity-matched groups.

Authors:  Rebecca S Campbell; Paresh Chaudhari; Harlen D Hays; Robert J Taylor; Brian H Nathanson; Samuel A Bozzette; David L Horn
Journal:  Clinicoecon Outcomes Res       Date:  2013-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.